A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas
Clinical trial NCT03763149 · COMPLETED
Trial details
- NCT number
- NCT03763149
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-02-19
- Primary completion
- 2021-03-29
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.